Please wait...
Please wait...
Sir Mike Rawlins
Chairmain of NICE
United Kingdom
Scrip 100: Sir Mike Rawlins on industry innovation
On innovations relating to anticancer products, Sir Mike Rawlins tells Elizabeth Sukkar: "[The innovators] have to do the best science they can, with the tools at their disposal". The GCP guidelines have never been revised since they were introduced 14 years ago, are evidence-free, and that imposes a huge burden. Among other things, he points out that the GCP was created without the consultation of academia, where "20 to 25 percent of the trials are done by academics. They were never involved in
Legal Disclaimers
Important Notice
Information and opinions contained in this broadcast have been compiled or arrived at by the organisation making this presentation.
This broadcast is hosted, streamed and brought to you by 3B NEXUS who make no representation or warranty regarding the accuracy or reliability or completeness of any information provided and accepts no liability for any loss arising from the use hereof. Any reliance you place on such information will be at your sole risk.
Forward-Looking Statements
The information, statements and opinions contained in this broadcast do not constitute a public offer under any applicable legislation or an offer to sell or solicitation of any offer to buy any securities or financial instruments or any advice or recommendation with respect to such securities or other financial instruments.
Any statements, information and opinions contained in this broadcast, in particular those concerning investments and the possible or assumed future performance, costs, dividends, returns, production levels or rates, prices, reserves, divestments, growth or other trend projections and any estimated earnings are or may contain certain forward looking statements and as such involve risks and uncertainties.
Actual results and developments may differ materially from those expressed or implied by these statements depending on a variety of factors.
